Aclaris Therapeutics (NASDAQ: ACRS) reported Q1 EPS of ($0.31), $0.09 better than the analyst estimate of ($0.40). Revenue for the quarter came in at $1.5 million versus the consensus estimate of $1.66 million.

For earnings history and earnings-related data on Aclaris Therapeutics (ACRS) click here.